28-30 January 2019
Paris, France
View Event Guide

Workshop A
Monday 28 January

10.00 - 12.30
Harnessing the Human Microbiome to Treat IBD

Initiation and progression of Inflammatory Bowel Disease (IBD) caused by compositional shifts in the gut microbiome have been extensively studied by both the research and industrial community. With over a decade of extensive metagenomic studies and other important analyses, the scientific community have an increased mechanistic understanding of the interactions between the host, the gut microbiome and their respective role in IBD development.

This interactive workshop will give you an opportunity to learn:

 

  • The current progress in microbiome research to address IBD treatment
  • See recent examples from rCDI, UC and Crohn’s to show where the microbiome community can take learnings from FMT successes to help shape the next generation of IBD treatments through the human microbiome?
  • Discuss how IBD patients maybe classified by specific pathobiont taxa as source of disease initiation/progression
  • Role of precision medicine to develop tailored microbiome-based therapeutics
  • Reviewing early R&D tools including animal models to better elucidate mechanisms of IBD pathogenesis and enable clearer clinical outcomes

Workshop Leader:

Jessica Schneider
Associate Scientific Director
Takeda

 

Workshop B
Monday 28 January

10.00 - 12.30
Harnessing the Human Microbiome to Treat Respiratory Disease

Although relatively unexplored, the access to culture-independent techniques for microbial investigation has shown that the lung microbiome presents itself as a promising target for pulmonary disease research, including COPD.

This interactive workshop will give you an opportunity to learn:

  • The role of the lung microbiome in respiratory disease
  • Observational studies in clinical cohorts that show promising associations between lung microbial composition and COPD
  • Proposed mechanisms for the lung microbiome’s contribution to COPD pathogenesis
  • How the lung microbiome differs to other body sites and how this can be leveraged for novel treatment options

Workshop Leader:

Jim Brown
Director of Computational Biology Senior Fellow
GSK

 

Workshop C
Monday 28 January

14.00 - 16.30
Harnessing the Human Microbiome to Treat CNS Disorders

Emerging data suggests that there is a link between changes in the gut microbiome and the treatment of neurological disease. This interaction workshop will outline recent scientific advances in unravelling the gut-brain connections and potential pathways to harness these findings for novel therapeutic approaches.

Join this interactive workshop to:

 

  • Learn what we know about the connection between gut microbiota and the brain and how these findings have created a new paradigm of how we think about neurological diseases
  • Probe data and experience from the broader microbiome space and the translational attempts in other therapeutic indications
  • Discuss the path forward and critical steps towards developing a new class of therapeutics

Workshop Leader:

Pr Sahar Aidy
Groningen Biomolecular Sciences and Biotechnology Institute
University of Groningen

 

Workshop D
Monday 28 January

14.00 - 16.30
Harnessing the Human Microbiome to Treat Cancer

As the microbiome continues to impact multitude of critical disease states, investigations focused on the relationship between microbiome composition and cancer development have been rapidly
evolving. However, these studies have primary focused on correlative relationships rather than causative.

With insights from industry and clinical experts, this interactive workshop will give you an opportunity to learn:

  • The role of the microbiome in cancer initiation and progression
  • Impact on drug metabolism and efficacy of cancer therapeutics currently in use
  • Review the mechanisms of microbiota-influenced carcinogenesis using in-vitro, in-vivo and clinical results
  • The challenges of performing microbiome research in oncology patients
  • How insights gained from the human microbiome can be ultimately exploited for the therapeutic benefit in cancer treatment